Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32681724 | 0.82 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL2984964 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL2647731 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL3070906 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL1793474 | 0.81 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL23366416 | 0.79 | DGAT1 (0.35) | DGAT1 | |
| Hydrochloric Acid SCHEMBL928416 | 0.79 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL9592717 | 0.79 | KCNH2 (0.37) | DGAT1 | |
| Hydrochloric Acid SCHEMBL4213606 | 0.79 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1792504 | 0.79 | DGAT1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675606-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2017-06-13 | — | — | US | disclosed |
| EP-2874625-B1 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-9376432-B2 | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | SANOFI (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2015-11-19 | — | — | US | disclosed |
| US-9126972-B2 | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20150183780-A1 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| EP-2709996-B1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI SA (FR) | 2015-06-24 | — | — | EP | disclosed |
| EP-2874625-A1 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA | SANOFI (FR) | 2015-05-27 | — | — | EP | disclosed |
| EP-2504338-B1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-2709996-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | SANOFI (FR) | 2014-03-26 | — | — | EP | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7125878-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2006-10-24 | — | — | US | disclosed |
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| EP-1506192-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMAECUTICA, NV (BE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003095452-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-20 | — | — | WO | disclosed |
| EP-0397365-A1 | Arylthiazolylimidazoles as 5HT3 Antagonists | PFIZER INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| US-4914207-A | ANTIEMETICS | PFIZER INC. (US) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328205-A1 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS | KDR, FLT4, FLT1 | DGAT1 4726/4885 |
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | DGAT1 2934/4885 |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | DGAT1 2934/4885 |
| US-20150183780-A1 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA | FLT4, FLT1, KDR | DGAT1 3104/4885 |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | DGAT1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.